Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in… read more.
The American Society of Hematology (ASH) released guidelines on the management of myelofibrosis, a rare and life-threatening blood cancer. ASH’s new guidelines recommend expanded molecular testing, early transplant… read more.
Bristol Myers Squibb announced first time presentation of results from the prespecified analysis of the pivotal Phase 3 EXCALIBER-RRMM trial (NCT04975997) evaluating ZENBEXUS (iberdomide) in combination with daratumumab… read more.
Children living with sickle cell anaemia have no higher incidence of clinically diagnosed infections when treated with hydroxyurea. New research shows the efficacy and safety of hydroxyurea treatment… read more.
Bristol Myers Squibb announced positive topline results from the Phase 3 EXCALIBER-RRMM study, evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) in 800 patients with multiple… read more.
GERPAC Congress 2026 highlights A mechanical spring-driven pump for subcutaneous daratumumab improved ergonomics for nurses and reduced injection pain for patients, according to Wendy Johnson (Department of Pharmacy,… read more.
NICE(UK): Isatuximab plus pomalidomide and dexamethasone can be used as an option to treat relapsed and refractory multiple myeloma in adults if: i) they have had 3 previous… read more.
AbbVie announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September… read more.
Johnson & Johnson announced the FDA approval of IMAAVY (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a rare, life-threatening autoantibody disease – in adults… read more.
Patients’ responses to questions routinely raised by oncologists may provide important clues about their chances of survival from chronic lymphocytic leukemia (CLL), according to a new study published in the… read more.
Takeda announced FDA approval of the New Drug Application (NDA) for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. Mimrylo… read more.
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation announced the FDA has approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making it the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
